A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Vaborbactam (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions
- Sponsors Rempex Pharmaceuticals
- 15 Aug 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 23 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2013 Official title amended as reported by ClinicalTrials.gov.